Common Contracts
2 similar Exclusive License and Development Agreement contracts by Sagimet Biosciences Inc.
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT by and between and Ascletis BioScience Co. Ltd. Dated January 18, 2019Exclusive License and Development Agreement • June 23rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is executed as of January 18, 2019 by and between 3-V Biosciences, Inc., a corporation organized under the laws of Delaware (“3-V”), having a principal place of business at 3715 Haven Ave. Suite 220, Menlo Park, CA 94025, and Ascletis BioScience Co. Ltd. (also known as 歌礼生物科技（杭州）有限公司), a corporation under the laws of China having a registered office at Room 1102，Building D，198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou, China (“Ascletis”). 3-V and Ascletis are sometimes collectively referred to herein as the “Parties” or individually as a “Party”.
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT by and between and Ascletis BioScience Co. Ltd. Dated January 18, 2019Exclusive License and Development Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Hong Kong
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is executed as of January 18, 2019 by and between 3-V Biosciences, Inc., a corporation organized under the laws of Delaware (“3-V”), having a principal place of business at 3715 Haven Ave. Suite 220, Menlo Park, CA 94025, and Ascletis BioScience Co. Ltd. (also known as 歌礼生物科技（杭州）有限公司), a corporation under the laws of China having a registered office at Room 1102，Building D，198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou, China (“Ascletis”). 3-V and Ascletis are sometimes collectively referred to herein as the “Parties” or individually as a “Party”.
